UPDATE: Goldman Sachs Upgrades C.R. Bard as Elements Driving Sell Thesis are Resolved
UPDATE: Goldman Sachs Downgrades NuVasive as Industry Headwinds, Valuation Pose Downside Risk
UPDATE: Goldman Sachs Downgrades Globus Medical as Execution, Share Gains are Offset by Valuation
UPDATE: Goldman Sachs Upgrades Thoratec on Good Upside Potential
David H. Roman Recent News
UPDATE: Goldman Sachs Upgrades Zeltiq Aesthetics on Good Upside from Current Levels
UPDATE: Goldman Sachs Downgrades Intuitive Surgical on Disappointing 2Q2013 Results
UPDATE: Goldman Sachs Downgrades Hill-Rom Holdings on Outperformance
UPDATE: Goldman Sachs Announces Neutral Rating on Covidien to Reflect New MNK Spin Off
Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences Following Detailed Thesis Review
UPDATE: Goldman Sachs Upgrades Abbott Laboratories; Growth Is Poised To Accelerate
UPDATE: Goldman Sachs Downgrades Thoratec Accounting on Challenged Outer Year Growth